Dark

XBIT
XBiotech Inc
stock NASDAQ

Market Open

Aug 11, 2026 12:36:26 PM EDT

2.27USD+0.220%(+2.27)13,505

1.93Bid 2.65Ask 0.72Spread

Pre-market

0.00USD-100.000%(-2.27)0

After-hours

Aug 7, 2026 4:00:30 PM EDT

2.27USD-0.220%(-0.01)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 26, 2022

09:53AM EST XBiotech Announces First Patient Enrolled In Phase 1 Clinical Trial For Novel Arthritis Therapy Natrunix Benzinga

Jan 13, 2022

11:44AM EST Lombard International Assurance S.A. Discloses 6.92% Passive Stake In XBiotech Benzinga

Dec 13, 2021

08:46AM EST XBiotech Launches Novel True Human Antibody Therapy Natrunix To Treat Rheumatology RTTNews

08:03AM EST XBiotech Announces FDA's Division Of Rheumatology Has Authorized Co. To Commence Clinical Development Of Natrunix Benzinga

08:00AM EST FDA Approves XBiotechs IND in Rheumatology GlobeNewswire Inc

Oct 28, 2021

12:03PM EDT XBiotech Highlights Launch Of Novel Candidate Therapy for Stroke Benzinga

09:34AM EDT XBiotech Sponsored Study Titled 'Hutrukin Safety PK Study' Posted To ClinicalTrials.gov; Study Not Yet Recruiting Benzinga

Oct 7, 2021

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

Oct 6, 2021

07:33AM EDT The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal Benzinga

Oct 5, 2021

08:01AM EDT The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout Benzinga

Sep 30, 2021

07:43AM EDT The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug Benzinga

Sep 29, 2021

08:13AM EDT The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug Benzinga

Sep 23, 2021

07:57AM EDT The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data Benzinga

Sep 21, 2021

08:20AM EDT The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data Benzinga

Sep 8, 2021

09:15AM EDT XBiotech Says Dr. Benjamin Musher To Chair Phase 1-2 Study Evaluating Co's Natrunix Anti-Cancer Therapy In Pancreatic Cancer Benzinga

09:00AM EDT Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating GlobeNewswire Inc

Aug 30, 2021

09:00AM EDT XBiotech Announces Addition of Dr. Mark Ziats, M.D. Ph.D. as GlobeNewswire Inc

Jul 30, 2021

11:03AM EDT XBiotech Inc. (NASDAQ: XBIT) (XBiotech) has completed payment to holders of its Common Stock of a previously announced dividend in the amount of USD$75,000,000.00. Based on the number of shares of Common Stock issued and outstanding on the record date for the dividend, each such holder received USD$2.47 per share on July 23, 2021. GlobeNewswire Inc

Jul 7, 2021

07:41AM EDT The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend Benzinga

Jul 6, 2021

04:30PM EDT XBiotech Inc.s (NASDAQ: XBIT) (XBiotech) Board of Directors has declared an extraordinary cash dividend of approximately $2.50 per share, or up to an aggregate of $75 million, to holders of its common stock. This one-time, special dividend will be payable on July 23, 2021 to stockholders of record at the close of business on July 16, 2021. GlobeNewswire Inc

Jun 30, 2021

11:47AM EDT XBiotech Announces Receipt of $75 Million from Sale of Antibody GlobeNewswire Inc

Jun 23, 2021

08:31AM EDT XBiotech Announces First Patient Enrolled In Clinical Trial Evaluating XB2001 For Treatment Of Pancreatic Cancer Benzinga

08:30AM EDT XBiotech Inc. (NASDAQ: XBIT) has enrolled the first patient in its 1-BETTER study, a randomized, double-blind, placebo-controlled clinical study to evaluate XB2001 in combination chemotherapy for treatment of Pancreatic Cancer. GlobeNewswire Inc

May 3, 2021

08:01AM EDT French National Cancer Institute And XBiotech To Conduct Innovative Phase II/III Adaptive Multicenter Clinical Study For XBiotech's New Cancer Drug For Colorectal Cancer Benzinga

08:00AM EDT XBiotech (NASDAQ: XBIT) announced today that it had reached an agreement to supply its new cancer drug XB20-01 to INSERM, and its Federation of Digestive Oncology group, a French organization which supports world-leading innovation for treating colorectal cancer. GlobeNewswire Inc

Apr 19, 2021

01:24PM EDT XBiotech shares were trading higher after the company announced that the FDA granted permission for its candidate therapy for the Phase1/2 double-blind placebo-controlled study in pancreatic cancer. Benzinga

07:09AM EDT XBiotech To Test New Drug Candidate Combined With Approved Treatment In Pancreatic Cancer Benzinga

05:32AM EDT FDA Granted Permission for XBiotech's Candidate Therapy for Phase I/II Double-blind Placebo Controlled Study in Pancreatic Cancer Benzinga

04:26AM EDT XBiotech (XBIT) said the FDA has granted permission to commence clinical trials with its drug candidate for treating patients with pancreatic cancer. The phase I/II study will evaluate the company's new drug candidate when added to the ONIVYDE/5-FU combination therapy. RTTNews

04:15AM EDT XBiotech: FDA Grants Permission To Commence Clinical Trials With XB2001 For Pancreatic Cancer RTTNews

04:00AM EDT FDA Gives Go-Ahead for XBiotechs Candidate GlobeNewswire Inc

Mar 3, 2021

05:20AM EST COVID-19 Convalescent Plasma Study Shows No Benefit, US NIH Stops Trial Benzinga

Mar 1, 2021

09:49AM EST A Look Into Healthcare Sector Value Stocks Benzinga

Jan 21, 2021

09:56AM EST XBiotech Inc. (XBIT) shares are rising on Thursday morning trade as the biopharmaceutical company reported that its COVID-19 candidate True Human antibody therapy may also be used for treating the COVID-19 mutant virus that recently emerged in the UK and is now rapidly spreading across the US. RTTNews

08:16AM EST XBiotech Shares Spike Higher; Co Says Candidate True Human COVID-19 Therapy Found To Target Highly Infectious Emerging Strain Benzinga

08:15AM EST XBiotech Candidate True Human COVID-19 Therapy GlobeNewswire Inc

Jan 19, 2021

08:40AM EST XBiotech Announces Cerebrovascular Medical Advisory Board & Development Of New Stroke Therapy Benzinga

08:15AM EST XBiotech Announces Cerebrovascular Medical Advisory Board & GlobeNewswire Inc

Nov 19, 2020

08:20AM EST XBiotech Announces Data Showing Effectiveness Of FLUVID Therapy In COVID-19 Benzinga

08:15AM EST XBiotech Data Shows Effective Anti-Virus Activity for True Human GlobeNewswire Inc

Sep 21, 2020

09:11AM EDT XBiotech Inc. (XBIT) said the company is developing a new therapy, FLUVID, for treating illness caused by combined infections with influenza and COVID-19. This therapy will combine XBiotech's influenza True Human antibodies together with its recently discovered COVID-19 antibodies into one treatment. RTTNews

08:38AM EDT XBiotech Says Developing New Breakthrough Candidate Therapy It Calls FLUVID RTTNews

08:22AM EDT XBiotech Says Is Developing FLUVID For 'treating illness caused by combined infections with influenza and COVID-19' Benzinga

08:20AM EDT XBiotech Developing True Human Antibody Combination as Candidate GlobeNewswire Inc

Aug 24, 2020

10:25AM EDT Shares of XBiotech Inc. (XBIT) are gaining over 12% on Monday morning after the U.S FDA authorized emergency use of antibody-rich COVID-19 therapy derived from convalescent patients. RTTNews

09:05AM EDT XBiotech Inc. (XBIT) announced the FDA issued an emergency use authorization for COVID-19 Convalescent Plasma as a COVID-19 treatment, opening the door for the company's antibody screening technology used to identify Convalescent Plasma. Under Collaboration, BioBridge Global will be using XBiotech's COVID-19 antibody test to identify the convalescent blood products. RTTNews

08:15AM EDT XBiotech Says COVID-19 Test 'Supports Convalescent Blood Treatments Now Approved Under FDA Emergency Use Authorization' Benzinga

08:10AM EDT FDA has Authorized Use of Antibody-Rich COVID-19 Therapy Derived from Convalescent Patients GlobeNewswire Inc

Aug 17, 2020

08:47AM EDT XBiotech Inc. (XBIT) said Monday that it has identified True Human antibodies that could potentially be used as a therapy against SARS-CoV2, the virus that causes COVID-19. It discovered those antibodies through a collaboration with BioBridge Global. RTTNews

08:24AM EDT XBiotech Says Has 'identified True Human antibodies that could potentially be used as a therapy against SARS-CoV2' Benzinga

08:24AM EDT XBiotech Says Identified True Human Antibodies That Could Be Used As COVID-19 Candidate Therapy RTTNews

08:20AM EDT XBiotech Discovers COVID-19 Candidate Therapy GlobeNewswire Inc

Aug 3, 2020

01:15PM EDT 5 Value Stocks In The Healthcare Sector Benzinga

Jul 22, 2020

09:22AM EDT XBiotech Reports Achievement Of Milestone In Development Of Inflammation-Fighting True Human Antibodies: Co. Permitted To Pursue Discovery Of New True Human Anti-IL-i Antibodies for Use In All Areas Of Medicine Except Dermatology Benzinga

09:20AM EDT XBiotech Achieves Milestone for Production of its New Potential GlobeNewswire Inc

Jul 14, 2020

09:33AM EDT XBiotech Announces Discovery That Blocking Interleukin-1a Reduces Brain Injury, Neurological Deficit After Stroke Benzinga

09:25AM EDT XBiotech Announces Discovery that Blocking Interleukin-1a Reduces GlobeNewswire Inc

document.getElementById("lkJDln").onerror = function(){this.style.display='none';}; .dark-mode .cFZB0L{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .cFZB0L{ color: #333333; background-color: white; border: 2px solid #333333; }XBITXBiotech Incstock NASDAQ

XBIT
XBiotech Inc
stock NASDAQ